Astria Therapeutics Inc., a biopharmaceutical company specializing in therapies for allergic and immunologic diseases, has announced the issuance of stock options under its 2022 Inducement Stock Incentive Plan. On June 2, 2025, the company granted options to purchase 62,000 shares of its common stock to two new employees as an inducement for joining the company. The options carry an exercise price of $4.78, matching the closing stock price on the grant date, and are scheduled to vest over four years. Initially, 25% of the shares will vest on the first anniversary of the employees' start date, with the remainder vesting monthly over the subsequent 36 months, contingent upon continued employment with Astria. These options are governed by the terms of the 2022 Inducement Stock Incentive Plan and specific award agreements.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。